Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer

Fig. 2

Lipid identification in advanced NSCLC patients in the PR group. In advanced NSCLC patients, lipid identification was performed on the PR group. The analysis of sample composition within the PR group involved assessing the lipid volume in each lipid category before and after administering PD-1/PD-L1 inhibitors and anlotinib treatment. Statistical significance compared to pre-treatment patients was determined using Student’s t-tests. Asterisks indicate the existence of these noteworthy disparities when P -value was lower than 0.05

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X